Advances in BABE
In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.
- Application of Nano technology to improve bioavailabilty
- Innovative strategies
- Isotope drug studies in man
- Bioequivalence Criteria
- Risks in bioequivalence assessment
- Requirement to determine the active principle
- SUPAC: scale-up and for post-approval changes
- Relevance of bioequivalence in approving generic copies of drug products
- Electronic regulatory submission and review
- Drug application regulatory compliance
- New drug quality assessment
- Highly variable and low permeable drugs
- Complex generics
Related Conference of Advances in BABE
Advances in BABE Conference Speakers
Recommended Sessions
- Advances in BABE
- Assessment of Bioequivalence
- BA/BE of Biologics & Biosimilars
- Bioavailability Studies
- Bioequivalence Protocols : In vivo/ In vitro studies
- Bioequivalence Studies
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Clinical Trials
- Contract Research Organizations
- Factors Affecting Bioavailability
- Managing BA/BE Studies
- Nutrient Bioavailability
- Pharma Clinical Trials
- Pharmaceutical Industry: Entrepreneurs Investment Meet
- Regulatory Requirements for Bioequivalence
- Significance of BA/BE Studies
- Study Designs